NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 7 நாட்களுக்கு முன்இன்று 36 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
CORONA Q2 FY27 Earnings Call Transcript: Revenue Up 22.2% YoY to ₹441 Cr, PAT at ₹60 Cr
CORONA Remedies released its Q2 & H1 FY27 earnings conference call transcript, detailing a 22.2% YoY growth in revenue to ₹441 crore compared to ₹361 crore in Q2 FY26. EBITDA grew 22.3% YoY to ₹96 crore with stable EBITDA margins at 21.7%, while PAT rose 15.3% YoY to ₹60 crore, dampened by higher depreciation and amortization from newly commissioned facilities and brand acquisitions. Domestic business contributed 97% of total revenue, outpacing the Indian pharmaceutical market with a 22.9% YoY increase. Management highlighted that NLEM exposure remains limited at ~7.5% of revenue, mitigating domestic price-cap risks.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the verbatim transcript of the Q2 & H1 FY27 post-earnings analyst conference call conducted on November 02, 2026.
ஏன் இது முக்கியம்Provides detailed management commentary on volume-led domestic outperformance, integration of acquired brands, therapy expansion (e.g., nephrology, CNS), and limited downside from price control regulations.
📅 குறுகிய காலம்The transcript reinforces strong operational momentum with 22%+ top-line growth, likely sustaining positive sentiment around quarterly earnings.
📈 நீண்ட காலம்Outperforming IPM volume growth (3.3x) and expanding into newer therapies support sustained long-term domestic formulation market share gains.
⚠ அபாய எச்சரிக்கைகள்
Depreciation and amortization drag from recent brand acquisitions and newly commissioned facilities compressing PAT growth relative to revenue.
Potential expansion of price controls (NLEM) across domestic formulations.
👀 கவனிக்க வேண்டியவை
Track the integration and performance of acquired brands such as Wokadine alongside margin evolution as new facility depreciation normalizes in upcoming quarters.
CORONA Remedies Q2 FY27 Net Profit Rises 15.3% to ₹60.3 Cr; Revenue Up 22.2% to ₹441.2 Cr
CORONA Remedies released its Q2 and H1 FY27 investor presentation showing strong top-line momentum. For Q2 FY27, revenue from operations grew 22.2% YoY to ₹441.2 Cr, while EBITDA increased 22.3% YoY to ₹96.0 Cr with an EBITDA margin of 21.7%. PAT rose 15.3% YoY to ₹60.3 Cr, slightly moderated by higher depreciation and amortization linked to new facilities and brand acquisitions. For H1 FY27, revenue reached ₹863.6 Cr with a PAT of ₹120.4 Cr and annualized ROCE of 49.8%.
உச்சம் நம்பிக்கை
என்ன மாறியதுCompany published its Q2 and H1 FY27 investor presentation outlining financial performance, therapeutic split, and operational milestones.
ஏன் இது முக்கியம்Demonstrates sustained >20% revenue growth and healthy 21.7% EBITDA margins, while advancing international regulatory approvals to support overseas expansion.
📅 குறுகிய காலம்Earnings show resilient double-digit operational growth and margin stability, keeping investor sentiment constructive.
📈 நீண்ட காலம்Expansion into international markets backed by EU-GMP and Brazil ANVISA accreditations alongside high domestic chronic therapy share (72.1%) supports structural earnings visibility.
⚠ அபாய எச்சரிக்கைகள்
Increased depreciation and amortization from acquisitions and new facilities exerting slight pressure on PAT margin
High domestic concentration with India representing 97.1% of H1 FY27 revenue
👀 கவனிக்க வேண்டியவை
Track capacity utilization and commercialization progress of the newly inaugurated Bhayla hormone facility and international regulatory rollouts following the ANVISA approval.
CORONA Remedies Q2FY27 Revenue Up 22.2% YoY to ₹441.2 Cr; EBITDA Margin Steady at 21.7%
CORONA Remedies reported a 22.2% YoY increase in consolidated revenue to ₹441.2 crore for Q2FY27, driven by domestic portfolio growth which outpaced the IPM by 1.9x. EBITDA grew 22.3% YoY to ₹96.0 crore, maintaining margins at 21.7%. PAT rose 15.3% YoY to ₹60.3 crore, compressed by higher depreciation and amortization charges from newly commissioned facilities and brand acquisitions. Additionally, the company secured ANVISA GMP certification from Brazil for its Bhayla manufacturing facility.
உச்சம் நம்பிக்கை
என்ன மாறியதுCORONA Remedies reported Q2 and H1 FY27 financial performance, delivering highest-ever quarterly revenues alongside receiving ANVISA certification for its Bhayla plant.
ஏன் இது முக்கியம்The company continues to outperform the Indian Pharmaceutical Market by ~1.9x with higher margins and expanding market rank (now 26th in overall IPM), while ANVISA certification opens potential export avenues in Latin America.
📅 குறுகிய காலம்Solid operational results with sustained 21%+ operating margins are likely to reinforce investor sentiment, though higher D&A temporarily moderated bottom-line growth relative to revenue.
📈 நீண்ட காலம்Expansion in chronic portfolios (71.2% mix) and regulatory approvals like ANVISA support management's strategy of outperforming domestic market growth and scaling global operations.
⚠ அபாய எச்சரிக்கைகள்
Elevated depreciation and amortization expenses weighing on near-term PAT margins until new capacities achieve optimal utilization
👀 கவனிக்க வேண்டியவை
Track whether newly commissioned capacities and acquired brands ramp up revenue contributions to offset increased depreciation in upcoming quarters, as well as export developments following the ANVISA approval.
CORONA Remedies Receives ANVISA Brazil GMP Approval for Bhayla Facility
CORONA Remedies has received Good Manufacturing Practice (GMP) certification from Brazil's ANVISA for its Bhayla (Ahmedabad) facility, covering Oral Solid Dosage (OSD) and Women's Hormone production lines. This marks the company's third major overseas GMP accreditation, complementing existing EU-GMP and EAEU-GMP approvals. While India currently drives over 96% of CORONA's revenue (TTM revenue at ₹1,479 Cr), the approval opens access to Brazil's estimated USD 44 billion pharmaceutical market. No immediate revenue contribution or order values were disclosed in the filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுCORONA's Bhayla manufacturing facility received ANVISA GMP compliance certification, enabling commercial exports of OSD and hormone formulations to Brazil.
ஏன் இது முக்கியம்Provides regulatory clearance to enter Latin America's largest pharma market (USD 44 billion), supporting the company's strategy to expand exports beyond its domestic base (>96% revenue).
Brazil pharma market size: USD 44 billionDomestic revenue share: >96%TTM வருவாய்: ₹1479 கோடி
📅 குறுகிய காலம்Positive sentiment for regulatory quality validation; however, immediate financial impact is minimal as commercial supply and product registrations take time.
📈 நீண்ட காலம்Enhances export optionality and diversifies geographical revenue away from the current heavy dependence on the Indian domestic formulations market.
⚠ அபாய எச்சரிக்கைகள்
Export gestation lag: product registrations and commercial rollouts in Brazil require additional regulatory timelines
Concentration risk: over 96% of revenue remains tied to the domestic Indian market
👀 கவனிக்க வேண்டியவை
Track future product dossier filings or distribution tie-ups in Brazil, and watch for export revenue contributions in upcoming quarterly results.
CARE Upgrades Short-Term Rating to A1+, Reaffirms A+; Stable on ₹77 Cr Facilities
CARE Ratings has revised and upgraded CORONA Remedies Limited's short-term rating on its ₹70.00 crore bank facilities from CARE A1 to CARE A1+. The long-term rating of CARE A+; Stable was reaffirmed, while rated long-term term loan facilities reduced to ₹7.00 crore from ₹25.00 crore following repayments. Total rated bank facilities stand at ₹77.00 crore, representing just ~10% of TTM revenue (₹776 crore).
உச்சம் நம்பிக்கை
என்ன மாறியதுCARE upgraded CORONA's short-term bank facility rating from A1 to A1+ and reduced rated long-term facilities to ₹7.00 crore.
ஏன் இது முக்கியம்The upgrade reflects improved liquidity and short-term debt servicing capability, potentially lowering short-term borrowing and working capital financing costs.
Total rated bank facilities: ₹77.00 கோடிLong-term / Short-term facilities: ₹70.00 கோடிLong-term facilities (term loans): ₹7.00 கோடிRated facilities vs TTM revenue: ~9.92%
📅 குறுகிய காலம்Marginally positive sentiment for the stock given the improved credit profile, though financial impact in the near term is limited due to modest total debt.
📈 நீண்ட காலம்Demonstrates balance sheet strength and operational discipline as the company continues to repay term debt and sustain healthy cash flows.
👀 கவனிக்க வேண்டியவை
Track subsequent quarterly updates to monitor whether lower borrowing costs from the short-term rating upgrade translate to improved net margins.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
21.9% Revenue Growth in Q1 FY27; New ₹130 Cr Hormonal Facility Commercialized
CORONA Remedies reported a robust Q1 FY27 with revenue growth of 21.9% YoY, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 11.6%. The company successfully commercialized its new ₹130 crore EU-GMP approved hormonal manufacturing facility, which is expected to drive international expansion starting FY29. Volume growth stood at 6.3%, nearly 5x the IPM average of 1.3%, while chronic and semi-chronic therapies now constitute 73.4% of the portfolio. Management expects the new facility to achieve an asset turnover of 2-3x within the next three years.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully commercialized a major ₹130 crore hormonal facility and outperformed market growth rates across all four key therapeutic segments.
ஏன் இது முக்கியம்The new facility represents a significant capacity expansion (capex is ~37% of FY26 revenue) and provides a gateway to high-margin regulated international markets, potentially diversifying the revenue base beyond India.
📅 குறுகிய காலம்The stock may see positive momentum following the earnings outperformance and the successful commissioning of the new manufacturing facility.
📈 நீண்ட காலம்Structural growth is expected as the company enters regulated markets (FY29 target) and leverages its backward integration with La Chandra Pharma Lab for hormonal APIs.
⚠ அபாய எச்சரிக்கைகள்
Regulatory compliance risks for the EU-GMP facility
Execution risk in entering competitive international markets
👀 கவனிக்க வேண்டியவை
Monitor the execution of dossier filings for the EU and other regulated markets scheduled for November-December 2026, as this will dictate the timeline for international revenue contribution.
21.9% Revenue Growth: CORONA Remedies Reports Strong Q1 FY27 with 30.1% PAT Increase
CORONA Remedies reported a strong start to FY27 with standalone revenue growing 21.9% YoY to ₹422.43 cr. Profitability saw a significant boost as PAT rose 30.1% YoY to ₹60.10 cr, supported by EBITDA margins expanding 190 bps to 22.0%. The company improved its market position to 26th in the Indian Pharmaceutical Market (IPM) and commenced commercialization of its new EU-GMP approved Female Hormone facility on June 30, 2026. Integration of the recently acquired Wokadine brand is currently underway to bolster the distribution network.
உச்சம் நம்பிக்கை
என்ன மாறியதுCORONA Remedies reported strong Q1 FY27 results exceeding market growth rates and operationalized a new specialized manufacturing facility.
ஏன் இது முக்கியம்The company is outperforming the Indian Pharmaceutical Market growth by 1.9 times, and the new EU-GMP facility provides a structural pathway for expansion into regulated international markets.
📅 குறுகிய காலம்The stock is likely to react positively to the double-digit growth in both top and bottom lines and the successful margin expansion.
📈 நீண்ட காலம்Long-term growth is supported by therapy leadership in Gynecology (ranked 5th) and the strategic shift toward regulated overseas markets via the new Ahmedabad facility.
⚠ அபாய எச்சரிக்கைகள்
Dependency on in-licensing partners for high-growth products
Potential regulatory risks associated with EU-GMP compliance for export expansion
👀 கவனிக்க வேண்டியவை
Investors should monitor the revenue contribution and margin impact of the newly commercialized Female Hormone plant and the progress of Wokadine brand integration in the coming quarters.
21.9% Revenue Growth in Q1 FY27; CORONA Remedies Ranks 26th in IPM
CORONA Remedies reported a strong Q1 FY27 with revenue growing 21.9% YoY to ₹422.4 cr and PAT increasing 30.1% to ₹60.1 cr. The company improved its Indian Pharmaceutical Market (IPM) rank to 26th, driven by its chronic portfolio which now contributes 73.4% of revenue. A significant operational milestone was the June 2026 inauguration of a new EU-GMP certified hormone facility in Gujarat with a capacity of 194 million units. Profitability improved notably with EBITDA margins expanding 190 bps to 22.0%.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported strong double-digit growth in Q1 FY27 and successfully commercialized a major new hormone manufacturing facility in Gujarat.
ஏன் இது முக்கியம்The shift toward a 73.4% chronic portfolio and the addition of specialized hormone manufacturing capacity are likely to sustain higher margins and support the company's goal of outperforming the broader pharmaceutical market.
📅 குறுகிய காலம்The stock is likely to react positively to the margin expansion and the successful commissioning of the new facility, which provides immediate growth visibility.
📈 நீண்ட காலம்The structural shift from acute to chronic therapies (now 73.4%) and the focus on specialized segments like hormones and infertility treatments position the company for sustainable long-term value creation.
⚠ அபாய எச்சரிக்கைகள்
Dependency on in-licensing partners like Ferring Pharmaceuticals for high-growth products
Regulatory compliance risks at the EU-GMP facility which is critical for export expansion
👀 கவனிக்க வேண்டியவை
Monitor the utilization levels and revenue contribution from the newly inaugurated hormone facility and the progress of entry into regulated overseas markets following the EU-GMP certification.
30.1% PAT Growth: CORONA Remedies Reports Strong Q1FY27 with ₹422.4 Cr Revenue
CORONA Remedies reported a strong start to FY27 with revenue growing 21.9% YoY to ₹422.4 Cr. Profitability improved significantly, with PAT rising 30.1% to ₹60.1 Cr and EBITDA margins expanding by 190 bps to 22.0%. The company improved its market ranking to 26th in the Indian Pharmaceutical Market (IPM) and inaugurated a new EU-GMP approved hormone plant on June 30, 2026. Integration of the recently acquired brand Wokadine is also underway to bolster distribution.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported strong Q1FY27 results with double-digit growth and inaugurated a major new manufacturing facility for regulated markets.
ஏன் இது முக்கியம்The results confirm CORONA's ability to outpace the broader pharmaceutical market (1.9x IPM growth) and its transition toward higher-margin regulated international markets.
📅 குறுகிய காலம்Positive sentiment is expected as the company delivered strong earnings growth and margin expansion alongside a new plant inauguration.
📈 நீண்ட காலம்Structural growth is supported by expansion into specialized therapies like Nephrology and CNS, and entry into regulated overseas markets via the new EU-GMP facility.
⚠ அபாய எச்சரிக்கைகள்
Integration risks of acquired brands like Wokadine
Regulatory compliance risks at the new EU-GMP Gujarat facility
👀 கவனிக்க வேண்டியவை
Monitor the revenue contribution and capacity utilization of the newly inaugurated Female Hormone plant and the successful integration of the Wokadine brand.
₹10 Final Dividend Approved at CORONA Remedies 22nd AGM; Chairman Re-appointed for 5 Years
CORONA Remedies concluded its 22nd AGM on July 09, 2026, approving a final dividend of ₹10 per share (100% of face value) for FY 2025-26. Shareholders adopted the FY26 financial statements, which included a March 2026 quarterly revenue of ₹353.09 cr and a net profit of ₹45.33 cr. Key leadership decisions included the re-appointment of Dr. Kirtikumar Mehta as Chairman for a 5-year term and the appointment of Walker Chandiok & Co LLP as Statutory Auditors. The company maintains its focus on expanding into high-growth therapeutic areas like Oncology and CNS while leveraging its EU-GMP certified Gujarat facility.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its FY26 financial results, confirmed a significant dividend payout, and secured leadership continuity with a 5-year term for the Chairman.
ஏன் இது முக்கியம்The appointment of a 'Big 6' auditor (Walker Chandiok) and the 100% dividend payout signal maturing corporate governance and a commitment to shareholder returns as the company scales its therapeutic presence.
Final Dividend: ₹10 per shareDividend % of Face Value: 100%Chairman Re-appointment Term: 5 yearsMar 2026 Quarterly Revenue: ₹353.09 கோடிMar 2026 Net Profit: ₹45.33 கோடி
📅 குறுகிய காலம்Neutral; the stock may see minor activity related to the dividend approval, but the proceedings are largely in line with standard annual requirements.
📈 நீண்ட காலம்Positive governance signal through the appointment of reputable auditors and leadership stability, supporting the company's target growth rate of 16.8%.
👀 கவனிக்க வேண்டியவை
Investors should monitor the upcoming disclosure of the dividend record date and track the company's execution in regulated overseas markets following its recent capacity expansion to 1.65 billion units.
20% Capacity Increase: CORONA Remedies Starts Production at EU-GMP Hormone Facility
CORONA Remedies has commenced commercial production at its new 1.0 lakh sq. ft. EU-GMP approved hormone manufacturing facility in Bhayla, Ahmedabad. The facility adds an annual capacity of 194 million tablets/capsules and 1.5 million ointments/gels, representing a ~20% increase in the company's in-house hormone manufacturing capacity. This specialized facility is designed for high-potency hormonal medicines, supporting multiple dosage forms including soft gel capsules and gels. The expansion aligns with the company's strategy to target regulated overseas markets and strengthen its position in the women's healthcare segment, which is one of its core therapeutic areas.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from the construction and validation phase to active commercial production at its specialized hormone manufacturing plant.
ஏன் இது முக்கியம்Hormone manufacturing is a high-barrier segment due to stringent contamination controls and specialized engineering requirements; this facility enables CORONA to scale its high-margin women's health portfolio globally.
New Tablet/Capsule Capacity: 194 million units p.a.New Ointment/Gel Capacity: 1.5 million units p.a.Hormone Capacity Increase: ~20%Facility Area: 1.0 lakh sq. ft.Mar 2026 Revenue: ₹ 353.09 cr
📅 குறுகிய காலம்The commencement of production is a positive milestone that validates the company's execution timeline; expect neutral to positive sentiment as the market factors in future volume growth.
📈 நீண்ட காலம்This is a structural expansion that supports the company's goal of entering regulated overseas markets and expanding into specialized areas like IVF and menopause management over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Regulatory compliance risks for EU-GMP standards
Execution risk in scaling high-potency API handling
Market competition in the women's healthcare segment
👀 கவனிக்க வேண்டியவை
Monitor the ramp-up of production at the Bhayla facility and track the company's progress in securing product-specific approvals for regulated overseas markets like the EU.
Corona Remedies to Hold 22nd AGM on July 9; Recommends ₹10 Dividend for FY 2025-26
Corona Remedies Limited has scheduled its 22nd Annual General Meeting (AGM) for July 9, 2026, via video conferencing. The Board of Directors has recommended a dividend of ₹10 per equity share (100% of face value) for the financial year ended March 31, 2026, which is subject to shareholder approval. The company is currently dispatching physical letters to shareholders who have not registered their email addresses, providing them with the web link to access the full Annual Report for FY 2025-26. Investors are encouraged to update their KYC and bank details to facilitate electronic dividend payments.
முக்கிய அம்சங்கள்
22nd Annual General Meeting scheduled for July 09, 2026, at 11:00 AM IST.Recommended dividend of ₹10 per equity share of ₹10 each for the financial year 2025-26.The dividend recommendation was finalized by the Board during their meeting on May 11, 2026.Annual Report for FY 2025-26 and AGM notice are available on the company's website.Shareholders must update KYC and bank details with Depository Participants to receive dividends electronically.
👀 கவனிக்க வேண்டியவை
Investors should review the FY 2025-26 Annual Report for operational performance and ensure their bank account details are updated with their DP to receive the ₹10 dividend.
CORONA Remedies FY26 Revenue Up 17% to ₹1,403 Cr; 22nd AGM Scheduled for July 09, 2026
CORONA Remedies reported a robust FY 2025-26 with revenue growing 17.28% to ₹1,403.18 crore, significantly outperforming the Indian Pharmaceutical Market (IPM) growth by 859 basis points. The company's PAT surged by 33.44% to ₹199.42 crore, driven by a high-margin chronic portfolio which now contributes 71.94% of total revenue. Strategic acquisitions of brands from Bayer Zydus and Dr. Reddy's have bolstered its presence in fertility and cardiac segments. The company maintains a strong financial profile with a ROCE exceeding 40% and a healthy net cash position.
முக்கிய அம்சங்கள்
Revenue from operations grew 17.28% YoY to ₹1,403.18 crore, while EBITDA rose 22.28% to ₹293.44 crore.The India business outperformed the IPM by 859 basis points, achieving 17.18% growth compared to the market's 8.59%.Chronic and sub-chronic therapies now account for 71.94% of revenue, enhancing margin stability and customer retention.Maintained superior capital efficiency with a Return on Capital Employed (ROCE) of over 40% and operating cash flow to EBITDA conversion of 78%.Strategic expansion included the acquisition of 7 brands from Bayer Zydus and the Wokadine brand from Dr. Reddy’s Laboratories.
👀 கவனிக்க வேண்டியவை
Investors should view the company's consistent market outperformance and high ROCE as strong indicators of execution capability. Monitor the upcoming commissioning of the new hormone facility and the integration of acquired brands for further growth catalysts.
CORONA Remedies Receives EU-GMP Certification for Hormone and OSD Facilities
CORONA Remedies Limited has secured EU-GMP Compliance Certification for its Hormone manufacturing facility and successfully renewed the EU-GMP approval for its Oral Solid Dosage (OSD) unit in Ahmedabad. These approvals follow a successful EUDRA GMP inspection conducted in April 2026. As one of India's top 30 pharmaceutical companies, this accreditation allows CORONA to export its specialized hormone portfolio to highly regulated European and global markets. The move aligns with their strategic vision to serve both domestic and international markets with uniform quality standards.
முக்கிய அம்சங்கள்
New EU-GMP certification granted for the Hormone manufacturing facility in Bhayla, AhmedabadSuccessful renewal of EU-GMP approval for the Oral Solid Dosage (OSD) manufacturing facilityCertifications follow a comprehensive EUDRA GMP inspection completed in April 2026CORONA Remedies is currently ranked among the Top 30 pharmaceutical corporates in IndiaAccreditation enables expansion into regulated and semi-regulated global markets for hormone therapies
👀 கவனிக்க வேண்டியவை
This is a significant positive development that enhances the company's export capabilities and margin potential; investors should monitor for increased international revenue contributions in upcoming quarters.
Corona Remedies Announces ₹10 Dividend; Sets June 19 Record Date for TDS
Corona Remedies Limited has recommended a final dividend of ₹10 per share (100% of face value) for FY 2025-26. The company has designated June 19, 2026, as the record date for determining shareholder eligibility and for the submission of tax-related documents. Resident shareholders will face a 10% TDS if their dividend exceeds ₹10,000, while a 20% rate applies for missing or unlinked PANs. Non-resident investors may access lower treaty rates by submitting required documentation like Tax Residency Certificates by the deadline.
முக்கிய அம்சங்கள்
Board recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26.June 19, 2026, is the record date for dividend payment and tax document submission.TDS of 10% applies to resident individuals with PAN for dividends over ₹10,000.A higher 20% TDS rate will be applied if PAN is not updated or linked with Aadhaar.Non-resident shareholders can claim tax treaty benefits by providing digital Form 41 and TRC.
👀 கவனிக்க வேண்டியவை
Shareholders should verify their PAN-Aadhaar linking and submit necessary tax exemption forms to the RTA by June 19 to optimize their net dividend receipt.
CORONA Remedies FY26 Revenue up 17% to ₹1,403 Cr, PAT Jumps 33%; Announces ₹10 Dividend
CORONA Remedies reported a robust FY26 performance with revenue growing 17.3% to INR 1,403 crores and adjusted PAT rising 33.4% to INR 199 crores, significantly outperforming the Indian Pharmaceutical Market (IPM). The company improved its industry ranking to 27th and declared a 100% dividend of INR 10 per share. Management has provided a strong outlook for FY27, guiding for 15%+ organic revenue growth and 20%+ PAT growth, supported by new launches in biosimilars and IVF segments.
முக்கிய அம்சங்கள்
FY26 Revenue grew 17.3% to INR 1,403 crores, while Adjusted PAT increased 33.4% to INR 199 crores.Full-year EBITDA margins improved by 80bps to 20.9%, despite a slight Q4 dip due to expansion investments.Achieved strong return ratios with RoCE at 41% and RoE at 29.2% for the fiscal year.Portfolio expansion includes two brands exceeding INR 100 crore and eight brands in the INR 50-100 crore club.Strategic entry into biosimilars with 4 launches and the establishment of a dedicated IVF taskforce.
👀 கவனிக்க வேண்டியவை
Investors should note the company's consistent ability to grow at 2x the industry rate and its high capital efficiency. The stock remains a strong growth-cum-dividend play in the domestic pharmaceutical space.
Corona Remedies Reports Full Compliance in FY26 Annual Secretarial Audit
CORONA Remedies Limited has released its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The independent audit conducted by M/s. Dhara Patel confirms that the company has adhered to all applicable SEBI regulations, including LODR and Insider Trading norms. No deviations, non-compliances, or penalties were reported by the auditor for the period. This clean report underscores the company's commitment to corporate governance and regulatory transparency.
முக்கிய அம்சங்கள்
Achieved 100% compliance with SEBI Regulations for the financial year ended March 31, 2026.Zero fines or penalties were imposed by SEBI or Stock Exchanges during the review period.Confirmed maintenance of a Structured Digital Database (SDD) in compliance with Insider Trading regulations.All related party transactions received prior approval from the Audit Committee.No instances of statutory auditor resignations or disqualification of directors were recorded.
👀 கவனிக்க வேண்டியவை
Investors can take confidence in the company's strong corporate governance and lack of regulatory friction. No immediate action is required as the report contains no adverse findings.
CORONA Remedies FY26 Adj. PAT Jumps 33.4% to ₹199.4 Cr; Outpaces Market Growth by 2x
CORONA Remedies reported a strong financial performance for FY26, with revenue growing 17.3% YoY to ₹1,403.2 Cr and adjusted PAT rising 33.4% to ₹199.4 Cr. The company is significantly outperforming the Indian Pharmaceutical Market (IPM), growing at 2.0x the industry average (17.2% vs 8.6%). Strategic acquisitions of Wokadine from Dr. Reddy's and seven brands from Bayer Zydus, funded via internal accruals, have strengthened its chronic portfolio, which now contributes ~72% of total revenue. With a net cash position and high return ratios (ROCE of 40.8%), the company is well-positioned for its expansion into Eurasian markets following recent EAEU-GMP certification.
முக்கிய அம்சங்கள்
FY26 Revenue grew 17.3% YoY to ₹1,403.2 Cr, while Adjusted PAT surged 33.4% to ₹199.4 Cr.EBITDA margins expanded by 80 bps to 20.9% for FY26, driven by execution excellence and brand strength.Strategic acquisitions of Wokadine and 7 Bayer Zydus brands completed using internal accruals, marking entry into the ₹6,481 Cr Povidone Iodine market.Bhayla facility received EAEU-GMP certification in Jan 2026, unlocking a ~USD 25 billion market opportunity in five Eurasian countries.Strong return ratios maintained with FY26 ROE at 29.2% and ROCE at 40.8% (excluding one-time labor code impact).
👀 கவனிக்க வேண்டியவை
Investors should note the company's superior execution, evidenced by growing at twice the industry rate and maintaining high return ratios while funding M&A through internal cash. The stock warrants a positive outlook given the successful shift to high-margin chronic therapies and the upcoming expansion into Eurasian markets.
Corona Remedies Recommends ₹10 Dividend; Sets June 19 as Record Date
CORONA Remedies has recommended a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26. The company has fixed June 19, 2026, as the record date to determine shareholder eligibility for this payout. Alongside the dividend, the board approved audited financial results for FY26 and announced the appointment of Walker Chandiok & Co LLP as the new statutory auditor for a five-year term. The dividend, if approved at the AGM, will be paid by August 07, 2026.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹10 per equity share of face value ₹10 (100%)Fixed June 19, 2026, as the record date for dividend entitlementAppointed Walker Chandiok & Co LLP as Statutory Auditors for a 5-year term starting FY27Re-appointed Dr. Kirtikumar Mehta as Chairman for a 5-year term effective April 01, 2027Dividend payment to be completed on or before August 07, 2026, subject to shareholder approval
👀 கவனிக்க வேண்டியவை
Investors seeking the ₹10 per share dividend should ensure they hold the stock prior to the June 19 record date. The transition to a top-tier statutory auditor like Walker Chandiok is a positive indicator for corporate governance.
Corona Remedies Limited has announced its audited financial results for the fiscal year ending March 31, 2026, alongside a significant dividend declaration. The Board recommended a final dividend of ₹10 per share (100% of face value), with the record date set for June 19, 2026. In a move to strengthen governance, the company appointed Walker Chandiok & Co LLP as its new statutory auditor for a five-year term. Additionally, Dr. Kirtikumar Mehta has been re-appointed as the Non-Executive Director and Chairman for another five years starting April 2027.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹10 per equity share (100% of face value) for FY 2025-26Set June 19, 2026, as the record date for dividend eligibility, with payment by August 07, 2026Re-appointed Dr. Kirtikumar Mehta as Chairman for a 5-year term effective April 1, 2027Appointed Walker Chandiok & Co LLP as Statutory Auditors for five consecutive years starting FY 2026-27Confirmed unmodified audit reports for both standalone and consolidated financial results for FY26
👀 கவனிக்க வேண்டியவை
Investors should ensure they hold shares by the June 19, 2026 record date to qualify for the ₹10 dividend. The transition to a top-tier audit firm and leadership continuity are positive indicators of corporate governance.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
